Finance

Lists
Why is 2359 down २.१९%?
Dive Deeper
2359:HKG
WuXi AppTec Ord Shs H
HK$ १९६.२०
-२.१९%
(-४.४०) 1D
अक्टोबर १६, १६:०८:१४ GMT+८  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2359...
Open
HK$ २०३.८०
High
HK$ २०९.००
Low
HK$ १८५.००
Mkt. cap
५.४५ खरब
Avg. vol.
३९.१० लाख
Volume
१.०२ करोड
Dividend
१.२२%
Quarterly dividend
HK$ ०.६०
Ex-dividend date
२०२६ सेप्टेम्बर ४
P/E ratio
२३.९८
52-wk high
HK$ २१९.२०
52-wk low
HK$ ९६.७०
EPS
HK$ ८.१८
No. of employees
३६ हजार
Open
HK$ २०३.८०
High
HK$ २०९.००
Low
HK$ १८५.००
Mkt. cap
५.४५ खरब
Avg. vol.
३९.१० लाख
Volume
१.०२ करोड
Dividend
१.२२%
Quarterly dividend
HK$ ०.६०
Ex-dividend date
२०२६ सेप्टेम्बर ४
P/E ratio
२३.९८
52-wk high
HK$ २१९.२०
52-wk low
HK$ ९६.७०
EPS
HK$ ८.१८
No. of employees
३६ हजार
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
१ घण्टा पहिले
Simply Wall St cuts target for WuXi AppTec stock to CNY 224.81
ad-hoc-news.de
ad-hoc-news.de
·
२ घण्टा पहिले
WuXi AppTec stock at EUR 22.03 ahead of the Xetra open: CRDMO group
ad-hoc-news.de
ad-hoc-news.de
·
१६ घण्टा पहिले
WuXi AppTec earns EcoVadis gold: what it means for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees३५.६ हजार
Founded२००० डिसेम्बर १
Headquarters-
Sector-
Last report
२०२६ अगस्ट ३
Fiscal period
Q2 2026
CN¥ २.२० / CN¥ १.३४
+६४.१८%beat
Revenue / Est. (CNY)
१६.४६ अरब / १२.८६ अरब
+२८.०३%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१२.०४ अरब
१०.९७ अरब
१२.४४ अरब
१६.४६ अरब
Cost of goods sold
६.०७ अरब
४.९१ अरब
६.१७ अरब
-
Cost of revenue
६.०७ अरब
४.९१ अरब
६.१७ अरब
-
Research and development expenses
३१.१७ करोड
२३.६९ करोड
२६.७० करोड
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
८५.४५ करोड
८५.३७ करोड
८९.१८ करोड
-
Operating expense
१.३८ अरब
१.२६ अरब
१.२२ अरब
-
Total operating expenses
७.४५ अरब
६.१७ अरब
७.३९ अरब
-
Operating income
४.५९ अरब
४.८० अरब
५.०४ अरब
-
Other non operating income
-४७.०४ करोड
२८.१४ करोड
-२६.६४ करोड
-
EBT including unusual items
५.१३ अरब
६.७५ अरब
५.६१ अरब
-
EBT excluding unusual items
५.११ अरब
६.९५ अरब
५.१९ अरब
-
Income tax expense
१.५५ अरब
१.०९ अरब
९३.६८ करोड
-
Effective tax rate
३०.१९%
१६.१२%
१६.७१%
-
Other operating expenses
५.८० करोड
२.५८ करोड
७.२६ लाख
-
Net income
३.५१ अरब
७.०८ अरब
४.६५ अरब
-
Net profit margin
२९.१८%
६४.४९%
३७.४०%
-
Earnings per share
१.२४
१.४२
१.५७
२.२०
Interest and investment income
१.२१ अरब
१.८७ अरब
४३.९८ करोड
-
Interest expense
-२२.६७ करोड
-
-३.१० करोड
-
Net interest expenses
९८.१७ करोड
१.८७ अरब
४०.८९ करोड
-
Depreciation and amortization charges
-
-
-
-
EBITDA
५.२१ अरब
५.६१ अरब
५.८५ अरब
-
Gain or loss from assets sale
-१५.८० करोड
२१.८४ करोड
-
-
AI content may include mistakes. Learn more
Google एपहरू